12:00 AM
 | 
Mar 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

RP5063: Phase II started

Reviva began the double-blind, placebo-controlled, international Phase II REFRESH trial to compare 15, 30 or 50 mg daily RP5063 vs. 15 mg daily aripiprazole in 228 patients. Bristol-Myers...

Read the full 128 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >